Association Between Smoking Status, and Free, Total and Percent Free Prostate Specific Antigen

Overview

Journal J Urol

Publisher Wolters Kluwer

Specialty Urology

Date 2012 Feb 17

PMID 22335864

Citations 14

Authors

Jun Li

Trevor Thompson

Djenaba A Joseph

Viraj A Master

Affiliations

Soon will be listed here.

Abstract

Purpose: There are scant data available on the relationship between smoking and total prostate specific antigen, free prostate specific antigen and percent-free prostate specific antigen. Given the high prevalence of smoking and the frequency of prostate specific antigen screening, it is important to determine any association between smoking and prostate specific antigen values using nationally representative data.

Materials And Methods: Included in the final study population were 3,820 men 40 years old or older who participated in the 2001-2006 NHANES (National Health and Nutrition Examination Survey) and met the eligibility criteria for prostate specific antigen testing. The distributions of total, free and percent free prostate specific antigen were estimated by sociodemographic and clinical characteristics. Multivariate linear regression models were fit to determine the adjusted relationship between smoking and total and percent free prostate specific antigen while simultaneously controlling for these characteristics.

Results: For all ages combined the median total and free prostate specific antigen levels were 0.90 (0.81-0.90) and 0.26 (0.25-0.28) ng/ml, respectively. Multivariate linear regression analysis showed that total prostate specific antigen was 7.9% and 12.2% lower among current and former smokers, respectively, than among never smokers. High body mass index and diabetes were also statistically significantly associated with a lower total prostate specific antigen. Approximately a third of the men had a percent free prostate specific antigen less than 25%. Current smokers had a significantly lower percent free prostate specific antigen than former smokers.

Conclusions: Our finding that smoking is inversely associated with total prostate specific antigen may have potential implications for the interpretation of prostate specific antigen levels in men who are current or former smokers. Given the high prevalence of smoking, obesity and diabetes, additional research on the combined effect of these health risk factors is warranted.

Citing Articles

Association of cigarette use with risk of prostate cancer among US males: a cross-sectional study from NHANES 1999-2020.

Yang X, Chen H, Zhang J, Zhang S, Wu Y, Pang J BMC Public Health. 2025; 25(1):608.

PMID: 39948519 PMC: 11827229. DOI: 10.1186/s12889-025-21863-9.

Study of HOXB13 Gene Variants in Prostate Cancer Patients.

Sulaiman K, Hama Salih R Cureus. 2024; 16(10):e72513.

PMID: 39606519 PMC: 11599774. DOI: 10.7759/cureus.72513.

Elevation of Serum Prostate-Specific Antigen Levels in Males With Pulmonary Embolism.

Peng Y, Ma L, Luo M Clin Appl Thromb Hemost. 2024; 30:10760296241250002.

PMID: 38779806 PMC: 11113070. DOI: 10.1177/10760296241250002.

Cigarette Smoking, Alcohol Consumption, and the Risk of Prostate Cancer-A Retrospective Analysis of Prostate Cancer Patients in Southern Nigeria.

Raphael J, Ekeke O Niger Med J. 2024; 62(6):346-352.

PMID: 38736515 PMC: 11087687. DOI: 10.60787/NMJ-62-6-66.

Advances and development of prostate cancer, treatment, and strategies: A systemic review.

Belkahla S, Nahvi I, Biswas S, Nahvi I, Ben Amor N Front Cell Dev Biol. 2022; 10:991330.

PMID: 36158198 PMC: 9501970. DOI: 10.3389/fcell.2022.991330.

References

Oesterling J, Jacobsen S, Chute C, Guess H, Girman C, Panser L . Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993; 270(7):860-4. View

Eastham J, May R, Whatley T, Crow A, Venable D, Sartor O . Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Inst. 1998; 90(10):756-60. DOI: 10.1093/jnci/90.10.756. View

Chang S, Harshman L, Presti Jr J . Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol. 2010; 28(25):3951-7. PMC: 2940393. DOI: 10.1200/JCO.2009.27.9406. View

Werny D, Thompson T, Saraiya M, Freedman D, Kottiri B, German R . Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev. 2006; 16(1):70-6. DOI: 10.1158/1055-9965.EPI-06-0588. View

. Screening for prostate cancer: recommendation and rationale. Ann Intern Med. 2002; 137(11):915-6. DOI: 10.7326/0003-4819-137-11-200212030-00013. View

Gray M, Delahunt B, Fowles J, Weinstein P, Cookes R, Nacey J . Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives. Anticancer Res. 2004; 24(3b):2069-72. View

Watters J, Park Y, Hollenbeck A, Schatzkin A, Albanes D . Cigarette smoking and prostate cancer in a prospective US cohort study. Cancer Epidemiol Biomarkers Prev. 2009; 18(9):2427-35. PMC: 2742569. DOI: 10.1158/1055-9965.EPI-09-0252. View

. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149(3):185-91. DOI: 10.7326/0003-4819-149-3-200808050-00008. View

Hickey K, Do K, Green A . Smoking and prostate cancer. Epidemiol Rev. 2001; 23(1):115-25. DOI: 10.1093/oxfordjournals.epirev.a000776. View

10.

Werny D, Saraiya M, Gregg E . Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol. 2006; 164(10):978-83. DOI: 10.1093/aje/kwj311. View

11.

Andriole G, Crawford E, Grubb 3rd R, Buys S, Chia D, Church T . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360(13):1310-9. PMC: 2944770. DOI: 10.1056/NEJMoa0810696. View

12.

Kristal A, Chi C, Tangen C, Goodman P, Etzioni R, Thompson I . Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase. Cancer. 2005; 106(2):320-8. DOI: 10.1002/cncr.21603. View

13.

Kenfield S, Stampfer M, Chan J, Giovannucci E . Smoking and prostate cancer survival and recurrence. JAMA. 2011; 305(24):2548-55. PMC: 3562349. DOI: 10.1001/jama.2011.879. View

14.

Loeb S, Roehl K, Antenor J, Catalona W, Suarez B, Nadler R . Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006; 67(2):316-20. DOI: 10.1016/j.urology.2005.08.040. View

15.

Schroder F, Hugosson J, Roobol M, Tammela T, Ciatto S, Nelen V . Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360(13):1320-8. DOI: 10.1056/NEJMoa0810084. View

16.

Gelmann E, Chia D, Pinsky P, Andriole G, Crawford E, Reding D . Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology. 2001; 58(4):561-6. DOI: 10.1016/s0090-4295(01)01305-x. View

17.

Partin A, Catalona W, Southwick P, Subong E, Gasior G, Chan D . Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology. 1996; 48(6A Suppl):55-61. DOI: 10.1016/s0090-4295(96)00611-5. View

18.

Field A, Colditz G, Willett W, Longcope C, McKinlay J . The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab. 1994; 79(5):1310-6. DOI: 10.1210/jcem.79.5.7962322. View

19.

Algotar A, Thompson P, Ranger-Moore J, Stratton M, Hsu C, Ahmann F . Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. Prostate. 2010; 70(8):883-8. PMC: 4527537. DOI: 10.1002/pros.21122. View

20.

. Vital signs: current cigarette smoking among adults aged >or=18 years --- United States, 2009. MMWR Morb Mortal Wkly Rep. 2010; 59(35):1135-40. View